Ireland
--:--IST
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Zhejiang Yangli Pharmaceutical Technology clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Zhejiang Yangli Pharmaceutical Technology as lead sponsor. Synced 5 Oct 2026
3Current trials
2Recruiting now
0Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Zhejiang Yangli Pharmaceutical Technology is the lead sponsor of 3 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 2. The most-studied condition is Hypertension.

ClinicalTrials.gov trials by status

  • Recruiting267%
  • Not yet open133%

Trials by phase

  • Phase 2133%
  • Phase 1133%
  • Phase 1/2133%
01

Clinical trials sponsored by Zhejiang Yangli Pharmaceutical Technology

3 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
NCT07254481 · ClinicalTrials.gov ↗ · Hypertension
Phase 1 Recruiting 2025-10 China
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
NCT06819215 · ClinicalTrials.gov ↗ · Cancer, Neoplasms, Neoplasms, Breast
Phase 1/2 Recruiting 2024-10 China
A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension
NCT07833098 · ClinicalTrials.gov ↗ · Hypertension, Resistant Hypertension, Uncontrolled Hypertension
Phase 2 Not yet open 2026-09 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Zhejiang Yangli Pharmaceutical Technology trials

7 conditions
Hypertension2Resistant Hypertension1Uncontrolled Hypertension1Cancer1Neoplasms1Neoplasms, Breast1Tumor1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in China32

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Hypertension

SponsorTrials
Medtronic Vascular6
ReCor Medical6
Aktiia5
China National Center for Cardiovascular Diseases5
Peking University5
Shanghai Jiao Tong University School of Medicine3
Beijing Friendship Hospital3
Shanghai 10th People's Hospital3
Jing Liu3
Korea University Anam Hospital3

Sponsors with the most current trials registered for this condition.

05

Questions about Zhejiang Yangli Pharmaceutical Technology trials

How many clinical trials does Zhejiang Yangli Pharmaceutical Technology sponsor?

Zhejiang Yangli Pharmaceutical Technology is the lead sponsor of 3 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 5 October 2026. Completed and withdrawn studies are not counted.

Are Zhejiang Yangli Pharmaceutical Technology trials recruiting?

Yes. 2 of its 3 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 5 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.